Center for Biologics Evaluation and Research Relocates - - BioPharm International

ADVERTISEMENT

Center for Biologics Evaluation and Research Relocates



In an effort to consolidate, FDA is moving the offices and laboratories of the Center for Biologics Evaluation and Research (CBER) from their current locations in Bethesda and Rockville, Maryland to the FDA White Oak campus in Silver Spring, Maryland. Most offices will commence moving on or about April 25, 2014, and will complete the move on or about May 18, 2014. Laboratories and remaining offices are scheduled to move in late June through August. In order to facilitate continuity of operations, one division, the Division of Biological Standards and Quality Control, within the Office of Compliance and Biologics Quality, will remain in its present location in Kensington, Maryland and move after processes assuring the availability of 2014-2015 seasonal influenza virus vaccine are completed.

Source: FDA

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines

Click here